| Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials I Garcia-Doval, G Carretero, F Vanaclocha, C Ferrandiz, E Daudén, ... Archives of dermatology 148 (4), 463-470, 2012 | 207 | 2012 |
| Consensus document on the evaluation and treatment of moderate‐to‐severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology E Daudén, L Puig, C Ferrándiz, JL Sánchez‐Carazo, ... Journal of the European Academy of Dermatology and Venereology 30, 1-18, 2016 | 123 | 2016 |
| Infections in moderate to severe psoriasis patients treated with biological drugs compared to classic systemic drugs: findings from the BIOBADADERM registry P Dávila-Seijo, E Dauden, MA Descalzo, G Carretero, JM Carrascosa, ... Journal of Investigative Dermatology 137 (2), 313-321, 2017 | 119 | 2017 |
| Body mass index in patients with moderate‐to‐severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry JM Carrascosa, M Vilavella, I Garcia‐Doval, G Carretero, F Vanaclocha, ... Journal of the European Academy of Dermatology and Venereology 28 (7), 907-914, 2014 | 90 | 2014 |
| Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5‐year observational study of clinical practice: 2008–2013 results of the … G Carretero, C Ferrandiz, E Dauden, F Vanaclocha Sebastian, ... Journal of the European Academy of Dermatology and Venereology 29 (1), 156-163, 2015 | 72 | 2015 |
| Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry C Medina, G Carretero, C Ferrandiz, E Dauden, F Vanaclocha, ... Journal of the European Academy of Dermatology and Venereology 29 (5), 858-864, 2015 | 59 | 2015 |
| Estudio bibliométrico de la revista Actas Dermo-Sifiliográficas (1984-2003) II. Análisis de las referencias bibliográficas J Miralles, JM Ramos, R Ballester, I Belinchón, A Sevila, M Moragón Actas Dermo-Sifiliográficas 96 (9), 563-571, 2005 | 58 | 2005 |
| Adherence and patient satisfaction with topical treatment in psoriasis, and the use, and organoleptic properties of such treatments: a Delphi study with an expert panel and … L Puig, JM Carrascosa, I Belinchón, V Fernández-Redondo, G Carretero, ... Actas Dermo-Sifiliográficas (English Edition) 104 (6), 488-496, 2013 | 55 | 2013 |
| Latent tuberculosis infection and active tuberculosis in patients with psoriasis: A study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in … AI Sánchez‐Moya, I García‐Doval, G Carretero, J Sánchez‐Carazo, ... Journal of the European Academy of Dermatology and Venereology 27 (11), 1366 …, 2013 | 54 | 2013 |
| Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia B Sanchez-Gonzalez, JC Pascual-Ramirez, P Fernandez-Abellan, ... Blood, The Journal of the American Society of Hematology 101 (6), 2446-2446, 2003 | 54 | 2003 |
| Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases … E Daudén, G Carretero, R Rivera, C Ferrándiz, M Llamas-Velasco, ... Journal of the American Academy of Dermatology 83 (1), 139-150, 2020 | 52 | 2020 |
| Epidemiology of leprosy in Spain: the role of the international migration JM Ramos, D Romero, I Belinchón PLoS neglected tropical diseases 10 (3), e0004321, 2016 | 52 | 2016 |
| Gender differential on characteristics and outcome of leprosy patients admitted to a long-term care rural hospital in South-Eastern Ethiopia JM Ramos, M Martínez-Martín, F Reyes, D Lemma, I Belinchón, ... International Journal for Equity in Health 11, 1-7, 2012 | 50 | 2012 |
| Clinical spectrum of COVID-19 and risk factors associated with severity in Spanish children A Tagarro, E Cobos-Carrascosa, S Villaverde, FJ Sanz-Santaeufemia, ... European journal of pediatrics, 1-11, 2022 | 42 | 2022 |
| Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective … I García‐Doval, MV Hernández, F Vanaclocha, A Sellas, P de la Cueva, ... British Journal of Dermatology 176 (3), 643-649, 2017 | 42 | 2017 |
| Evolution of cooperation patterns in psoriasis research: Co-authorship network analysis of papers in Medline (1942–2013) G González-Alcaide, J Park, C Huamani, I Belinchon, JM Ramos PloS one 10 (12), e0144837, 2015 | 41 | 2015 |
| Spanish adaptation of the European guidelines for the evaluation and treatment of actinic keratosis C Ferrándiz, E Fonseca-Capdevila, A García-Diez, C Guillén-Barona, ... Actas Dermo-Sifiliográficas (English Edition) 105 (4), 378-393, 2014 | 41 | 2014 |
| Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: a cross-sectional study in clinical practice JM Carrascosa, I Garcia-Doval, B Pérez-Zafrilla, G Carretero, ... Journal of Dermatological Treatment 26 (6), 502-506, 2015 | 39 | 2015 |
| Prevalence and characteristics of neuropathic pain in leprosy patients treated years ago JM Ramos, B Alonso-Castañeda, D Eshetu, D Lemma, F Reyes, ... Pathogens and global health 108 (4), 186-190, 2014 | 37 | 2014 |
| Cost‐effectiveness of treatment of superficial basal cell carcinoma: surgical excision vs. imiquimod 5% cream F Vanaclocha, E Daudén, X Badía, C Guillén, JS Conejo‐Mir, ... British Journal of Dermatology 156 (4), 769-771, 2007 | 35 | 2007 |
